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Objectives. We sought to determine whether the ameliorative
effects of microtubule depolymerization on cellular contractile
dysfunction in pressure overload cardiac hypertrophy apply at the
tissue level.
Background. A selective and persistent increase in microtubule
density causes decreased contractile function of cardiocytes from
cats with hypertrophy produced by chronic right ventricular (RV)
pressure overloading. Microtubule depolymerization by colchicine
normalizes contractility in these isolated cardiocytes. However,
whether these changes in cellular function might contribute to
changes in function at the more highly integrated and complex
cardiac tissue level was unknown.
Methods. Accordingly, RV papillary muscles were isolated from
25 cats with RV pressure overload hypertrophy induced by
pulmonary artery banding (PAB) for 4 weeks and 25 control cats.
Contractile state was measured using physiologically sequenced
contractions before and 90 min after treatment with 1025 mol/liter
colchicine.
Results. The PAB significantly increased RV systolic pressure
and the RV weight/body weight ratio in PAB; it significantly
decreased developed tension from 59 6 3 mN/mm2 in control to
25 6 4 mN/mm2 in PAB, shortening extent from 0.21 6 0.01
muscle lengths (ML) in control to 0.12 6 0.01 ML in PAB, and
shortening rate from 1.12 6 0.07 ML/s in control to 0.55 6 0.03
ML/s in PAB. Indirect immunofluorescence confocal microscopy
showed that PAB muscles had a selective increase in microtubule
density and that colchicine caused complete microtubule depoly-
merization in both control and PAB papillary muscles. Microtu-
bule depolymerization normalized myocardial contractility in
papillary muscles of PAB cats but did not alter contractility in
control muscles.
Conclusions. Excess microtubule density, therefore, is equally
important to both cellular and to myocardial contractile dysfunc-
tion caused by chronic, severe pressure-overload cardiac hyper-
trophy.
(J Am Coll Cardiol 1999;33:250–60)
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A cardinal molecular etiology of the contractile defects char-
acteristic of chronic pressure-overload hypertrophy of a degree
relevant to human pathophysiology is a selective and persistent
increase in the microtubule component of the extramyofila-
ment cytoskeleton (1–6). In earlier work, we found that right
ventricular (RV) pressure-overload hypertrophy (POH) causes
a decreased contractile state when measured in isolated RV
papillary muscle preparations (7), and that cardiac muscle
cells, or cardiocytes, isolated from RVPOH tissue exhibit an
equivalent degree of contractile dysfunction (8). In more
recent work, we found that RV and left ventricular (LV) POH
cause increased microtubule network density and up-
regulation of a-tubulin and b-tubulin, the major microtubule
proteins, on the mRNA and protein levels (1–4,6). Impor-
tantly, microtubule depolymerization in hypertrophied cardio-
cytes changed the cardiocyte contractile state, characterized in
terms of sarcomere and cellular mechanics, from clearly de-
pressed to entirely normal (1–4,6) by removing a viscous load
from the shortening sarcomeres (5). To date, however, the role
of excess microtubules in causing contractile dysfunction has
been examined only in isolated cardiocytes. The next logical
step in establishing the pathophysiological significance of this
cytoskeletal alteration would be to show that correction of the
cellular contractile state by microtubule depolymerization cor-
rects the myocardial contractile state when examined at the
more highly integrated and complex level of muscle tissue.
This rather straightforward goal is made more compelling
by the fact that the results of such a study are neither obvious
nor predictable on the basis of current data. That is, myocar-
dium is a complex tissue composed of cardiocytes admixed
with endothelial, neural, vascular, and interstitial cells. The
myocardial contractile deficits of chronic POH may be due to
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changes intrinsic or extrinsic to the cardiocyte. Extracardiocyte
factors such as loading conditions, extent of heterogeneity, and
neurohumoral factors may alter myocardial function; and
cardiocyte interactions with a denser connective tissue net-
work, decreased capillary density, and/or increased diffusion
distances may alter myocardial contractile state independent of
changes in cardiocyte properties. Intracardiocyte factors, in
addition to the extramyofilament cytoskeleton, such as calcium
homeostasis, energetics, and myosin ATPase isotypes, may also
influence myocardial function. Thus, it is entirely possible that,
despite the dramatic amelioration of contractile dysfunction
seen at the level of isolated cardiocytes, microtubule depoly-
merization might well not correct the myocardial contractile
dysfunction resulting from severe chronic pressure-overload
cardiac hypertrophy.
It is also possible that myocardial contractile defects might
be only incompletely corrected by microtubule depolymeriza-
tion, as in previous experiments most of the studies were
performed in freely contracting, completely unloaded cells
(1–4,6). Under such conditions, cardiocytes perform no exter-
nal work, consume little energy, and may exhibit preserved
shortening even under marginal conditions. To determine
maximum work capacity, contractile state should be assessed
under physiological conditions wherein cardiocytes shorten
against known, measurable, and variable loads. Because it is
possible that some level of contractile dysfunction might be
present but unrecognized in freely shortening, unloaded car-
diocytes, the completeness of any correction of myocardial
contractile state can only be determined in muscle prepara-
tions loaded in a physiological manner.
Thus, whether acute microtubule depolymerization would
correct myocardial as opposed to cellular contractile dysfunc-
tion remained an important but unanswered question. Because
our central goal was to determine whether this cytoskeletal
abnormality had a role in clinical heart disease, it was our
intent to go from the cell, to tissue, to the intact heart in animal
models and then to clinical studies of patients with POH. This
study, which constitutes the step from cell to tissue, was
designed to address the question of whether microtubule
depolymerization normalizes myocardial as opposed to cellular
contractile dysfunction in severe pressure-overload hypertro-
phy.
Methods
Right ventricular papillary muscles were isolated from cats
with RVPOH after pulmonary artery banding (PAB). Muscle
function was assessed using physiologically sequenced contrac-
tions at baseline and after colchicine treatment; colchicine
causes microtubule depolymerization by binding to b-tubulin
and preventing ab-tubulin polymerization into microtubules
(9). As the half-life of microtubules is '30 min, colchicine
causes a reduction in the number of microtubules over 30 to
90 min.
If excess microtubules cause contractile dysfunction in
hypertrophied myocardium, the same contractile dysfunction
should appear in normal myocardium if excess microtubule
polymerization is induced by a nonhemodynamic means, such
as treatment with taxol, an agent that increases microtubule
network density by lowering the critical concentration of
ab-tubulin heterodimers required to form microtubules (2).
Thus, RV papillary muscles were isolated from normal cats,
and myocardial function was assessed at baseline and after
treatment with taxol.
Pulmonary artery banding. Right ventricular POH was
induced as before (7) by partially occluding the pulmonary
artery with a 2.9-mm internal diameter band. Twenty-five adult
cats of random sex weighing 2.6 to 3.9 kg underwent PAB and
then recovered for 4 weeks. Twenty-five normal adult cats of
random sex served as controls.
Hemodynamic studies and papillary muscle isolation. At
final study, the cats were anesthetized, right heart pressures
were obtained, and arterial pressure was monitored. Arterio-
venous oxygen content was used as a measure of cardiac output
(7). The heart was then perfused with a Krebs-Henseleit
cardioplegia solution consisting of (mmol/liter): NaCl 98.0;
KCl 4.7; MgSO4 1.2; KH2PO4 1.1; NaHCO3 24.0; NaAc 20.0;
CaCl2 2.5; glucose 11.2; 2,3-butanedione monoxime (BMD)
30.0; and insulin 10 U/l. This solution, continuously bubbled
with 95% O2–5% CO2 at room temperature and pH 7.38, was
first infused as a 50-ml bolus over 1 min, causing cardiac
standstill, and then at a rate of 5 to 10 ml/min while 1 to 3 RV
papillary muscles were excised. A 6-0 silk suture was tied to the
top of each muscle at the chorda–muscle junction, and the base
was attached to a spring clip. The muscles were placed in
oxygenated cardioplegia solution for 30 min and then in this
cardioplegia solution without BDM for a 15-min washout
period before electrical stimulation was begun. Once the
papillary muscle was placed in the isolated muscle chamber,
and throughout the subsequent study, the temperature was
held at a constant 29°C.
Papillary muscle servo control system. After the washout
period, the muscle was electrically stimulated by parallel
platinum electrodes delivering 5-ms pulses at a voltage 10%
over threshold. The silk suture on the upper end of the
papillary muscle was attached to a Cambridge 300 B Servo
Control System, and the lower clip was attached to a semicon-
ductor strain gauge transducer (DSC-3; Kistler-Morse). A
digital computer with an analog–digital interface controlled
Abbreviations and Acronyms
BDM 5 2,3-butanedione monoxime
cAMP 5 adenosine 39:59-cyclic monophosphate
IBMX 5 3-isobutyl-1-methylxanthine
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either tension or length of the preparation. Tension and length
data were sampled at a rate of 1 kHz and stored for later
analysis. The precision of the force and length settings was
5 mg and 2 mm, respectively. The stepped response of the
system to an imposed length change was 95% complete in
2 ms. Equipment compliance was ,1.0 mm/mN.
Measurements of papillary muscle mechanics. At each
study point, papillary muscle function was assessed defining
three relationships: active force versus muscle length; shorten-
ing velocity versus force; and shortening extent versus force.
Muscle length was expressed as a percent of the length at peak
active tension (Lmax), and muscle load was normalized to the
cross-sectional area of the muscle (mN/mm2). At the end of
each study, muscle length (ML) was measured at the Lmax
preload. Muscle cross-sectional area was determined assuming
a uniform cross section, from muscle length at Lmax, muscle dry
weight, a wet-to-dry weight ratio of 4:1, and a specific gravity of
1.0. Muscles with cross-sectional areas ,0.5 mm2 or .1.5 mm2
were excluded from analysis, as previous studies have shown
that if cross-sectional area is ,1.5 mm2, there is no central core
hypoxia (10). There was no significant difference between
control versus experimental groups either in muscle length
(6.0 6 1.0 mm in normal vs. 6.2 6 1.0 mm in PAB) or in muscle
cross-sectional area (1.0 6 0.2 mm2 in normal vs. 1.2 6
0.3 mm2 in PAB).
Protocols used to assess myocardial function. Baseline.
Each papillary muscle was allowed to equilibrate by contract-
ing isotonically at a 0.5-g preload for 120 min; at 15-min
intervals the muscle was gradually stretched to Lmax, and
isotonic contractions at a 0.5-g preload and isometric contrac-
tions at the Lmax preload were studied. Mechanical equilibrium
was said to have occurred when muscle length at Lmax,
shortening extent during isotonic contraction, and active ten-
sion during isometric contraction were constant during three
consecutive measurements at 15-min intervals. Baseline values
were then recorded, Lmax was determined at baseline, and
isotonic, isometric, and graded physiologically sequenced con-
tractions were studied.
Colchicine. After the baseline measurements, colchicine
was added to the buffer to a final concentration of 1025
mol/liter. This concentration, which was higher then that used
in our isolated cardiocyte studies, was chosen to ensure
diffusion throughout the muscle. At 15-min intervals for a total
of 90 min, Lmax was determined, and isotonic, isometric, and
graded physiologically sequenced contractions were studied.
This protocol of 120 min of equilibrium followed by 90 min of
colchicine (Protocol A) was followed for 10 control muscles
from normal cats and for 10 hypertrophied muscles from PAB
cats. To show that the muscles were stable during the time
required for these studies, two normal and two PAB muscles
were examined over a 300-min period without colchicine
(Protocol B).
To then prove that the colchicine effect was specific, two
papillary muscles were isolated from each of three PAB cats.
In the first cat, the first papillary muscle was allowed to
equilibrate for 120 min and then treated with colchicine for
180 min; the second papillary muscle was allowed to equili-
brate for 120 min and then not treated with colchicine and was
reassessed throughout the subsequent 180 min (Protocol C). In
the second cat this order was reversed: the first papillary muscle
was allowed to equilibrate and then not treated with colchi-
cine; the second papillary muscle was allowed to equilibrate
and then treated with colchicine. In the third cat, the first
muscle was allowed to equilibrate for 210 min and then treated
with colchicine for 90 min; the second papillary muscle was
allowed to equilibrate for 120 min but then not treated with
colchicine and followed for a total of 300 min (Protocol D). By
studying two muscles from an individual animal, interanimal
variation was avoided, and the effects of colchicine could be
more specifically determined.
Taxol. After baseline measurements, taxol was added to
the buffer to achieve a final concentration of 1025 mol/liter. At
15-min intervals for a total of 4 h, Lmax was determined, and
isotonic, isometric, and graded physiologically sequenced con-
tractions were then studied.
Cytoskeletal characterization. In addition to demonstrat-
ing the effects on myocardial mechanics of interventions
designed to have selective effects on microtubules, the relative
amounts of free and polymerized b-tubulin in papillary mus-
cles were characterized by immunoblotting, and the appear-
ance and density of the cardiocyte microtubule network were
visualized by indirect immunofluorescence microscopy.
Immunoblots. Immunoblot analysis, using a monoclonal
b-tubulin antibody (Amersham), was performed on papillary
muscles isolated from the RVs of normal and PAB cats using
previously described methods (1–3). Papillary muscles were
processed immediately after isolation or after being treated
with colchicine (1025 mol/liter for 90 min) or taxol (1025
mol/liter for 4 h).
Indirect immunofluorescence confocal microscopy. The mi-
crotubule network was characterized in papillary muscles
isolated from normal and PAB cats in the baseline state after
treatment with colchicine. In addition, the microtubule net-
work was assessed in the RV free-wall tissue of normal and
PAB cats to ensure that papillary muscles were representative
of the myocardium as a whole. Of particular importance,
micrographs from the papillary muscles were taken from the
geometric center of the papillary muscle to ensure that
colchicine-induced microtubule depolymerization had oc-
curred throughout the entire muscle.
Micrographs were obtained in papillary muscles that were
immersion-fixed and in myocardial tissue, which was perfusion-
fixed with a periodate-lysine-paraformaldehyde fixative. After
blocking with 10% horse serum in 0.1 mol/liter glycine, the
sections were incubated with the monoclonal b-tubulin anti-
body and then with fluorescein isothiocyanate-labeled donkey
anti-mouse immunoglobulin. Optical sections ('0.7 mm) were
acquired by confocal laser scanning microscopy.
Intracellular calcium transients. Intracellular calcium
transients were measured in normal and PAB RV papillary
muscles with the Ca21-regulated bioluminescent indicator
aequorin using previously described methods (11). Aequorin
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solution (1 mg/ml; 1.0 to 1.5 ml) was pressure-injected through
a glass micropipette just beneath the endocardium of the
muscles. One hour after aequorin loading, when Ca21 tran-
sients and resting and developed tension were stable, the
muscles were stretched to Lmax and stimulated to contract
isometrically at 4-s intervals.
Measurements of cAMP. Adenosine 39:59-cyclic mono-
phosphate (cAMP) was measured by the manufacturer’s pro-
tocol using a cAMP [I125] assay (Amersham) in normal and
PAB papillary muscles under 1 of 6 protocols. In Protocol 1,
cAMP was measured in normal and PAB muscles immediately
after isolation. In Protocol 2, cAMP was measured in normal
and PAB muscles immediately after 60-min exposure to 1025
mol/liter colchicine. In Protocol 3, cAMP was measured in
normal and PAB muscles after 30-min exposure to 1025
mol/liter colchicine followed by 2-min concurrent exposure to
3-isobutyl-1-methylxanthine (IBMX). In Protocol 4, normal
and PAB muscles were kept in Krebs-Henseleit buffer for
30 min; IBMX was then added for 2 min, and cAMP levels
were measured. In Protocol 5, cAMP was measured in normal
and PAB muscles after 30-min exposure to 1025 mol/liter
colchicine. In Protocol 6, normal and PAB muscles were kept
in Krebs-Henseleit buffer for 30 min, and cAMP levels were
measured.
Data analysis. The mean and standard error are shown for
each group. Differences between group means at baseline and
following colchicine treatment, considered significant at p ,
0.05, were determined using a multiway analysis of variance
and a Newman-Keuls multiple sample comparison test.
Results
Effects of PAB on myocardial contractile function. The
effects of PAB on in vivo measures of pressure, oximetry, and
mass are shown in Table 1; the effects on in vitro myocardial
contractile functions are shown in Table 2 and Figures 1 to 4.
The in vivo data for normal and PAB cats are similar to those
in our previous studies (1–5,7,8), in that PAB caused signifi-
cant increases in RV systolic pressure and mass but did not
cause RV failure. Figures 1 and 2, examples of isotonic and
isometric contraction from normal and PAB muscles, show
that PAB caused marked decreases in both active tension
generation and shortening extent. Figure 3 shows that PAB
caused a marked decrease in active tension at all muscle
lengths. Figure 4, A shows that PAB caused a marked decrease
in the entire shortening extent versus force relationship, and
Figure 4, B shows that PAB caused a marked decrease in the
entire shortening velocity versus force relationship. Thus,
RVPOH causes a marked decrease in myocardial papillary
muscle contractility.
Effects of colchicine on myocardial contractile function.
Figures 1 to 4 show the effects of colchicine treatment on the
contractile state of normal and PAB papillary muscles. Colchi-
cine had no significant effect on the contractile state of normal
muscles. In these muscles, 90 min after exposure to colchicine,
active tension at Lmax was 63 6 5 mN/mm
2, shortening extent
at 0.5 g of force was 0.22 6 0.01 muscle lengths (ML), and
shortening velocity at 0.5 g of force was 1.24 6 0.14 ML/s. In
contrast, in hypertrophied PAB muscles, colchicine caused a
marked increase in contractile state. In PAB muscles, 90 min
after exposure to colchicine, active tension at Lmax was 55 6
Table 1. Characteristics of the Pulmonary Artery
Banding Model
Control
(n 5 12)
Pulmonary
Artery Band
(n 5 15)
RV Systolic pressure (mm Hg) 21 6 3 69 6 5*
DO2% Saturation (SVC vs. RA) 20.5 6 0.2 20.2 6 0.6
RV Weight/Body weight (g/kg) 0.52 6 0.04 1.10 6 0.05*
RV Weight/Tibial length (g/cm) 0.11 6 0.01 0.27 6 0.02*
LV Weight/Body weight (g/kg) 2.2 6 0.1 2.0 6 0.2
Body weight (kg) 2.4 6 0.1 2.7 6 0.1
Arteriovenous O2 difference (ml/l) 35.4 6 2.1 32.1 6 1.0
RV Diastolic pressure (mm Hg) 2 6 1 6 6 1
Liver weight/Body weight (g/kg) 24.2 6 1.0 26.7 6 1.2
Values are mean 6 SEM. Statistical comparisons are by unpaired Student t
test. SVC: superior vena cava; RA: right atrium. *p , 0.05 for difference from
control.
Table 2. Mechanical Characteristics of the Papillary Muscles
Control
(n 5 12)
Pulmonary Artery Band
(n 5 15)
Baseline Colchicine Baseline Colchicine
Active tension at Lmax (mN/mm
2) 59 6 3 63 6 5 25 6 4* 55 6 5†
Resting tension at Lmax (mN/mm
2) 12.00 6 0.04 12.00 6 0.04 14.00 6 0.04 14.00 6 0.04
Force development rate (mN/mm2/s) 26 6 2 29 6 3 11 6 1* 22 6 4†
Time to peak tension (ms) 390 6 24 374 6 19 461 6 16* 439 6 13*
Time to 50% relaxation (ms) 273 6 13 258 6 13 325 6 10* 255 6 10†
Shortening extent (ML) 0.21 6 0.01 0.22 6 0.01 0.12 6 0.01* 0.19 6 0.01†
Shortening velocity (ML/s) 1.12 6 0.07 1.24 6 0.14 0.55 6 0.03* 1.10 6 0.07†
Time to peak shortening (ms) 370 6 15 360 6 20 437 6 10* 430 6 14*
Values are mean 6 SEM. Statistical comparisons were made via multiway analysis of variance followed by a
Newman-Keuls multiple sample comparison test. *p , 0.05 for difference from control baseline; †p , 0.05 for difference
from PAB baseline.
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5 mN/mm2, shortening extent at 0.5 g of force was 0.19 6
0.01 ML, and shortening velocity at 0.5 g of force was 1.10 6
0.07 ML/s. Thus, the contractile defects present in hypertro-
phied papillary muscles from PAB cats were fully normalized
by treatment with colchicine.
Specificity of colchicine effects. Studies were done to prove
that the improvement in myocardial contractility was specific
to colchicine treatment and that time alone did not normalize
function. Figure 5 shows that the mechanical performance was
stable in both normal and hypertrophied papillary muscles.
Function reached equilibrium after 90 to 120 min and then
remained constant for up to 5 h.
We studied pairs of papillary muscles from three PAB cats.
In the first cat, the mechanical performance of both muscles
had reached equilibrium by 90 min. The first muscle was then
treated with colchicine at 120 min; contractile function was
abnormal initially but returned to normal at 90 min of colchi-
cine exposure and remained stable through 300 min (Figure 6,
papillary muscle 1). The second muscle was not treated with
colchicine; contractile function was abnormal initially and
remained abnormal through 300 min (Figure 6, papillary
muscle 2). In the second cat, the order of study of the papillary
muscle pair was changed, but the results were very similar. In
the third cat, mechanical performance of both muscles reached
equilibrium by 90 min. The first muscle was then treated with
colchicine at 210 min, after 120 min of stable but depressed
mechanical performance. After colchicine treatment contrac-
tility became normal (Figure 7, papillary muscle 1). The second
muscle was not treated with colchicine and showed character-
istic persistent contractile deficits (Figure 7, papillary muscle
2). Thus, the mechanical effects of colchicine are specific and
independent of the time of treatment.
Figure 2. Contractions of a PAB papillary muscle. Panel A: Shortening
extent during an isotonic contraction at baseline. Panel B: Shortening
extent during an isotonic contraction after colchicine. Panel C: Active
tension during an Lmax isometric contraction at baseline. Panel D:
Active tension during an Lmax isometric contraction after colchicine.
Figure 3. Relationship between developed force and muscle length in
normal papillary muscles before (closed circles) and after (open
circles) colchicine and in PAB papillary muscles before (closed
triangles) and after (open triangles) colchicine. *p , 0.05 vs. normal
baseline.
Figure 1. Contractions of a normal papillary muscle. Panel A: Short-
ening extent during an isotonic contraction at baseline. Panel B:
Shortening extent during an isotonic contraction after colchicine.
Panel C: Active tension during an Lmax isometric contraction at
baseline. Panel D: Active tension during an Lmax isometric contraction
after colchicine.
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Effects of taxol on myocardial contractile function. Figure
8 shows the effects of taxol on the contractile state of normal
papillary muscles. After 4 h of exposure to taxol, active tension
at Lmax was 27 6 8 mN/mm
2, shortening extent at 0.5 g of force
was 0.13 6 0.03 ML, and shortening velocity at 0.5 g of force
was 0.60 6 0.05 ML/s. Thus, taxol caused a contractile defect
in normal muscles equivalent to that seen in RVPOH muscles.
Cytoskeletal characterization. The immunoblots in Figure
9 show that at baseline hypertrophied muscles had an increase
in both free and polymerized b-tubulin when compared to
normal papillary muscles. In addition, treatment of either
normal of hypertrophied muscles with colchicine caused mi-
crotubule depolymerization. Finally, treatment of normal con-
trol papillary muscles with taxol increased the amount of
polymerized b-tubulin to levels comparable to those seen in
hypertrophied myocardium.
The micrographs in Figure 10 show that, compared to
muscles from normal cats (Panel A), muscles from PAB cats
exhibit an increase in the density of the microtubule network
(Panel C). Treatment of both normal muscles (Panel B) and
PAB muscles (Panel D) with 1025 mol/liter colchicine for
90 min caused nearly complete depolymerization of the micro-
tubules. The findings were similar when the microtubule
network was assessed in RV free-wall samples from normal
and PAB cats (data not shown). Of note, these data from
ventricular tissue and papillary muscles are identical to our
data from isolated cardiocytes both before and after colchicine
treatment.
Measurements of calcium transients and cAMP. Treating
papillary muscles isolated from normal and PAB cats with
Figure 4. Relationship between shortening extent and force (Panel A)
and shortening velocity and force (Panel B) in normal papillary
muscles before (closed circles) and after (open circles) colchicine and
in PAB papillary muscles before (closed triangles) and after (open
triangles) colchicine. *p , 0.5 vs. normal baseline.
Figure 5. Time-dependent changes in contractile state in normal
(circles) and PAB (triangles) papillary muscles. Upper Panel: Active
force. Lower Panel: Shortening velocity.
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colchicine did not augment either the intracellular calcium
transient or intracellular cAMP levels. Figure 11 shows that in
normal papillary muscles, colchicine caused a small decrease in
peak developed tension, which corresponded to a small de-
crease in peak activated calcium. Neither the rate of rise nor
the rate of decline in intracellular calcium was altered by
colchicine. In contrast, in hypertrophied papillary muscles,
although the prolonged calcium transient that we have seen
before with longer-term hypertrophy and most apparently at
supraphysiological [Ca21]o (11; Figure 1) was not observed,
colchicine caused a significant increase in peak developed
force but a small decrease in peak activation calcium, and no
significant change in either the rate of rise of the rate of decline
in intracellular calcium.
In each of the six cAMP protocols used, there were no
significant differences in cAMP between normal and hypertro-
phied muscles. For example, in freshly isolated muscles, cAMP
was 1.03 6 0.02 pmol/mg in normal and 0.93 6 0.01 pmol/mg
in hypertrophied muscles. After 90 min of treatment with 1025
mol/liter colchicine, cAMP was 0.60 6 0.02 pmol/mg in normal
and 0.47 6 0.01 pmol/mg in hypertrophied muscles. After 1025
mol/liter colchicine for 30 min, then IBMX for 2 min, cAMP
was 1.38 6 0.02 pmol/mg in normal and 0.99 6 0.02 pmol/mg
in hypertrophied muscles.
Figure 6. Time-dependent changes in contractile state in a pair of
papillary muscles from a PAB cat. Upper Panel: Active force. Lower
Panel: Shortening velocity. Papillary muscle 1 (open triangles) was
exposed to colchicine after mechanical performance had reached an
equilibrium at 120 min. Papillary muscle 2 (closed triangles) was not
exposed to colchicine.
Figure 7. Time-dependent changes in contractile state in a pair of
papillary muscles from a PAB cat. Upper Panel: Active force. Lower
Panel: Shortening velocity. Papillary muscle 1 (open triangles) was
exposed to colchicine at 210 min, 90 min after it had reached
mechanical equilibrium. Papillary muscle 2 (closed triangles) was not
exposed to colchicine.
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Discussion
Our previous studies suggested that a selective and persis-
tent increase in microtubules has an important causative role
in the transition from severe but compensated pressure-
overload cardiac hypertrophy to decompensated cardiac fail-
ure (1–6). However, the role of microtubules in causing
contractile dysfunction had been examined only in isolated
cardiocytes. The next logical step was to determine whether
correction of cardiocyte contractile function in situ by micro-
tubule depolymerization would correct myocardial contractile
dysfunction when examined at the more highly integrated and
complex level of cardiac tissue. We show here that RVPOH
caused a significant decrease in myocardial papillary muscle
contractility, which was associated with a marked increase in
the density of the microtubule portion of the extramyofilament
cytoskeleton. Depolymerization of these microtubules with
colchicine resulted in normalization of myocardial papillary
muscle contractility.
Furthermore, when excess microtubule polymerization was
created in normal myocardium by treatment with taxol, con-
tractile dysfunction developed in these normal papillary mus-
cles that was identical to that seen in chronic pressure-overload
hypertrophy. Thus, the abnormality in myocardial contractility
seen in severe chronic pressure-overload hypertrophy was
caused specifically by an increase in intracellular microtubules,
such that correction of cardiocyte contractile function by
microtubule depolymerization resulted in complete normaliza-
tion of the myocardial contractile state.
Figure 8. Time-dependent changes in contractile state in a normal
control papillary muscle (circles) and in a normal papillary muscle
treated with taxol (triangles). Upper Panel: Active force. Lower Panel:
Shortening velocity.
Figure 9. Immunoblots of normal and PAB papillary muscles. Data
are presented in pairs, with free (soluble) b-tubulin in lane 1 and
polymerized b-tubulin in lane 2 for each pair.
Figure 10. Immunofluorescence confocal micrographic analysis of
microtubules in normal and PAB papillary muscles. Panel A: Normal
muscle not exposed to colchicine. Panel B: Normal muscle after
colchicine. Panel C: PAB muscle not exposed to colchicine. Panel D:
PAB muscle after colchicine. Scale bar 5 25 mm.
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Role of microtubules in contractile dysfunction. Identify-
ing the mechanism or mechanisms that cause the transition
from compensated hypertrophy to compensated failure clearly
has important clinical implications and has been the subject of
intense and extensive investigation. Although the current study
was aimed specifically at defining the role that microtubules
play in this process, we and others have studied a number of
other molecular and cellular mechanisms that have been
postulated to contribute to the development of contractile
dysfunction in pressure-overload hypertrophy (7,12–14). In the
model of RVPOH used in the current study, abnormalities
have been identified in myocardial energetics, calcium ho-
meostasis, and the extracellular matrix (12–14). Further, a
number of other mechanisms have been identified in RV and
LV models of POH that may be pertinent to the current
RVPOH model, including changes in the myosin heavy-chain
and myosin light-chain isoforms and changes in the
b-adrenergic receptor pathway and in other receptor pathways
(12–14).
There are, then, a number of molecular, cellular, and
extracellular mechanisms, in this and other models of POH,
which might have causal roles in the development of myocar-
dial dysfunction. It is for this reason that the results of this
study were both unpredictable and surprising. We expected
that correcting cardiocyte microtubule hyperpolymerization
alone would only partially correct the abnormalities in myo-
cardial contractile state in this model. This prediction was
based on the assumption that each of the above mechanisms
would have some role in causing contractile dysfunction and
the fact that colchicine, acting specifically on microtubule
polymerization, would have no effect on the other mechanisms
noted earlier. It is thus remarkable that correcting microtubule
hyperpolymerization alone caused complete normalization of
myocardial contractile state on the tissue level, indicating that
Figure 11. Aequorin studies of RV papillary muscle intracellular
calcium transients. Upper Panel: Developed tension. Lower Panel:
Aequorin calcium light signal. Data were obtained at baseline (solid
line) and after treatment with colchicine (dashed line) in muscles from
normal and PAB cats.
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changes in microtubules play a predominant role not only in
cardiocyte but also in myocardial contractile dysfunction in
severe POH.
Nonetheless, although this study shows that microtubules
have the predominant role in causing contractile dysfunction in
this model or RVPOH, it is clear that microtubule hyperpoly-
merization is not the only mechanism responsible for the
transition from compensated cardiac hypertrophy to decom-
pensated cardiac failure. Instead, the role that microtubules
have in the development of contractile dysfunction appears to
be specific to POH in adult mammals in which wall stress in not
normalized (6). That is, an increase in the microtubule com-
ponent of the extramyofilament cytoskeleton is not a general-
ized response to hemodynamic overloading, such that it would
be expected that contractile dysfunction in many forms of
hemodynamic overloading would be caused by other molecular
and cellular abnormalities (1–4). Thus, although all cardio-
myopathic states are not related to changes in microtubules,
our studies have defined a specific set of clinically relevant
circumstances that do produce contractile dysfunction caused
by excessive microtubules. These circumstances are not limited
to the cat or to the RV, and these findings have been confirmed
by others. Cardiocytes isolated from a canine LV POH model
showed similar increases in microtubule polymerization and
similar decreases in contractile state, which were normalized
by depolymerization of the cardiocyte microtubules (6). In a
confirmatory study, Ishibashi et al. (15) showed similar results
using an adult rodent model of LV POH, as has Wang et al.
(16), and increased cardiocyte microtubule density has now
been found in end-stage LV failure in humans as well (17).
Specificity of colchicine effects. Our conclusion that micro-
tubules play a pivitol role in the development of contractile
dysfunction in POH is based in part on the assertion that
colchicine acts specifically through its effects on microtubule
depolymerization and not through a nonspecific, microtubule-
independent effect on contractile state. Data obtained from the
current study and from our previous studies clearly support
this hypothesis (1–6). These studies addressed three specific
issues: 1) does colchicine affect contractile state independent
of its effects of microtubules, 2) does colchicine affect intracel-
lular calcium homeostasis, and 3) does colchicine alter intra-
cellular cAMP?
Data from the current and previous studies (1–6) support
the conclusion that alterations in contractile state caused by
treating muscles and cardiocytes isolated from cats with POH
with colchicine are specific to microtubule depolymerization.
In these studies, microtubule depolymerization was accom-
plished using both chemical and physical means. For example,
microtubule depolymerization was induced in hypertrophied
cardiocytes by treatment with colchicine (a chemical approach)
or treatment with hypothermia (a physical approach). Al-
though both may have had other effects, the one effect that
these two very different approaches clearly shared was micro-
tubule depolymerization. Because both approaches normal-
ized the contractile dysfunction present in hypertrophied car-
diocytes, it is likely that this outcome was caused by the effect
they shared in common (microtubule depolymerization) and
was independent of other effects by which they differed. In
addition, if colchicine had direct inotropic effects, independent
of microtubule depolymerization, then its effects on contrac-
tility would have been greater than the effects of hypothermia.
Finally, colchicine would have caused significant changes in
contractile state in normal muscles or cells. Colchicine had
neither of these latter two effects.
Colchicine does not alter calcium homeostasis. We previ-
ously showed that colchicine does not increase either resting or
peak activated calcium levels in normal or hypertrophied
cardiocytes (2). The current study using aequorin-labeled
papillary muscles shows that colchicine does not increase the
peak activated calcium level or the rate of rise or fall of
intracellular calcium.
Colchicine does not alter intracellular cAMP levels. These
findings are in concordance with a study performed in isolated
leukocytes which showed that treatment with colchicine alone
did not significantly affect cAMP levels (18). Colchicine did
potentiate the effect of specific drugs on cAMP levels on
leukocytes. Thus, colchicine pretreatment caused the action of
b-adrenergic agonists, prostaglandin E, and phosphodiesterase
inhibitors on cAMP to be markedly increased when compared
to the effects of these drugs when leukocytes were not pre-
treated with colchicine. However, no changes in b-adrenergic
tone, prostaglandin, or phosphodiesterase levels would be
expected to occur in the current isolated muscle preparation.
Therefore, the lack of change in cAMP in response to colchi-
cine in our papillary muscle preparation was an expected
outcome.
Conclusions. Chronic RVPOH causes a significant de-
crease in papillary muscle contractility, which in turn is caused
by a significant increase in the microtubule portion of the
extramyofilament cardiocyte cytoskeleton. Acute depolymer-
ization of these excessive microtubules with colchicine normal-
ized myocardial papillary muscle contractility. These changes
in microtubule density and polymerization state are equally
important both to cardiac tissue and to cardiac cellular con-
tractile state. Thus, these specific and persistent cardiocyte
microtubule abnormalities have a critical role in the changes in
myocardial contractility that occur during severe chronic pres-
sure overload cardiac hypertrophy.
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